5:19 PM
 | 
Aug 30, 2012
 |  BC Extra  |  Company News

Ariad submits ponatinib MAA

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) submitted an MAA to EMA for ponatinib to treat resistant or intolerant chronic myelogenous leukemia...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >